Neuromyelitis Optica Drug Market - Global Outlook and Forecast 2021-2027

January 2021 | 104 pages | ID: N43B5C1DF986EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Neuromyelitis Optica Drug in Global, including the following market information:
Global Neuromyelitis Optica Drug Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Neuromyelitis Optica Drug market was valued at 36 million in 2020 and is projected to reach US$ 40 million by 2027, at a CAGR of 2.9% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuromyelitis Optica Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuromyelitis Optica Drug Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Neuromyelitis Optica Drug Market Segment Percentages, By Type, 2020 (%)

• Glucocorticoids
• Immunotherapies
• Other

China Neuromyelitis Optica Drug Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Neuromyelitis Optica Drug Market Segment Percentages, By Application, 2020 (%)

• Acute Attack
• Remission Prophylactic Treatment

Global Neuromyelitis Optica Drug Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Neuromyelitis Optica Drug Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Neuromyelitis Optica Drug Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Neuromyelitis Optica Drug Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Pfizer
• Fresenius
• Teva
• Sandoz
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL
• Grifols
• Octapharma
• CBOP

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neuromyelitis Optica Drug Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neuromyelitis Optica Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROMYELITIS OPTICA DRUG OVERALL MARKET SIZE

2.1 Global Neuromyelitis Optica Drug Market Size: 2021 VS 2027
2.2 Global Neuromyelitis Optica Drug Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neuromyelitis Optica Drug Players in Global Market
3.2 Top Global Neuromyelitis Optica Drug Companies Ranked by Revenue
3.3 Global Neuromyelitis Optica Drug Revenue by Companies
3.4 Top 3 and Top 5 Neuromyelitis Optica Drug Companies in Global Market, by Revenue in 2020
3.5 Global Companies Neuromyelitis Optica Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Drug Players in Global Market
  3.6.1 List of Global Tier 1 Neuromyelitis Optica Drug Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Drug Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Neuromyelitis Optica Drug Market Size Markets, 2021 & 2027
  4.1.2 Glucocorticoids
  4.1.3 Immunotherapies
  4.1.4 Other
4.2 By Type - Global Neuromyelitis Optica Drug Revenue & Forecasts
  4.2.1 By Type - Global Neuromyelitis Optica Drug Revenue, 2016-2021
  4.2.2 By Type - Global Neuromyelitis Optica Drug Revenue, 2022-2027
  4.2.3 By Type - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neuromyelitis Optica Drug Market Size, 2021 & 2027
  5.1.2 Acute Attack
  5.1.3 Remission Prophylactic Treatment
5.2 By Application - Global Neuromyelitis Optica Drug Revenue & Forecasts
  5.2.1 By Application - Global Neuromyelitis Optica Drug Revenue, 2016-2021
  5.2.2 By Application - Global Neuromyelitis Optica Drug Revenue, 2022-2027
  5.2.3 By Application - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Neuromyelitis Optica Drug Market Size, 2021 & 2027
6.2 By Region - Global Neuromyelitis Optica Drug Revenue & Forecasts
  6.2.1 By Region - Global Neuromyelitis Optica Drug Revenue, 2016-2021
  6.2.2 By Region - Global Neuromyelitis Optica Drug Revenue, 2022-2027
  6.2.3 By Region - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Neuromyelitis Optica Drug Revenue, 2016-2027
  6.3.2 US Neuromyelitis Optica Drug Market Size, 2016-2027
  6.3.3 Canada Neuromyelitis Optica Drug Market Size, 2016-2027
  6.3.4 Mexico Neuromyelitis Optica Drug Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Neuromyelitis Optica Drug Revenue, 2016-2027
  6.4.2 Germany Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.3 France Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.4 U.K. Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.5 Italy Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.6 Russia Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.7 Nordic Countries Neuromyelitis Optica Drug Market Size, 2016-2027
  6.4.8 Benelux Neuromyelitis Optica Drug Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Neuromyelitis Optica Drug Revenue, 2016-2027
  6.5.2 China Neuromyelitis Optica Drug Market Size, 2016-2027
  6.5.3 Japan Neuromyelitis Optica Drug Market Size, 2016-2027
  6.5.4 South Korea Neuromyelitis Optica Drug Market Size, 2016-2027
  6.5.5 Southeast Asia Neuromyelitis Optica Drug Market Size, 2016-2027
  6.5.6 India Neuromyelitis Optica Drug Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Neuromyelitis Optica Drug Revenue, 2016-2027
  6.6.2 Brazil Neuromyelitis Optica Drug Market Size, 2016-2027
  6.6.3 Argentina Neuromyelitis Optica Drug Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Drug Revenue, 2016-2027
  6.7.2 Turkey Neuromyelitis Optica Drug Market Size, 2016-2027
  6.7.3 Israel Neuromyelitis Optica Drug Market Size, 2016-2027
  6.7.4 Saudi Arabia Neuromyelitis Optica Drug Market Size, 2016-2027
  6.7.5 UAE Neuromyelitis Optica Drug Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Neuromyelitis Optica Drug Major Product Offerings
  7.1.4 Pfizer Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.1.5 Pfizer Key News
7.2 Fresenius
  7.2.1 Fresenius Corporate Summary
  7.2.2 Fresenius Business Overview
  7.2.3 Fresenius Neuromyelitis Optica Drug Major Product Offerings
  7.2.4 Fresenius Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.2.5 Fresenius Key News
7.3 Teva
  7.3.1 Teva Corporate Summary
  7.3.2 Teva Business Overview
  7.3.3 Teva Neuromyelitis Optica Drug Major Product Offerings
  7.3.4 Teva Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.3.5 Teva Key News
7.4 Sandoz
  7.4.1 Sandoz Corporate Summary
  7.4.2 Sandoz Business Overview
  7.4.3 Sandoz Neuromyelitis Optica Drug Major Product Offerings
  7.4.4 Sandoz Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.4.5 Sandoz Key News
7.5 Intas
  7.5.1 Intas Corporate Summary
  7.5.2 Intas Business Overview
  7.5.3 Intas Neuromyelitis Optica Drug Major Product Offerings
  7.5.4 Intas Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.5.5 Intas Key News
7.6 Gyjtrs
  7.6.1 Gyjtrs Corporate Summary
  7.6.2 Gyjtrs Business Overview
  7.6.3 Gyjtrs Neuromyelitis Optica Drug Major Product Offerings
  7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.6.5 Gyjtrs Key News
7.7 NANG KUANG
  7.7.1 NANG KUANG Corporate Summary
  7.7.2 NANG KUANG Business Overview
  7.7.3 NANG KUANG Neuromyelitis Optica Drug Major Product Offerings
  7.4.4 NANG KUANG Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.7.5 NANG KUANG Key News
7.8 Tianjin Kingyork
  7.8.1 Tianjin Kingyork Corporate Summary
  7.8.2 Tianjin Kingyork Business Overview
  7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Major Product Offerings
  7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.8.5 Tianjin Kingyork Key News
7.9 Baxter
  7.9.1 Baxter Corporate Summary
  7.9.2 Baxter Business Overview
  7.9.3 Baxter Neuromyelitis Optica Drug Major Product Offerings
  7.9.4 Baxter Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.9.5 Baxter Key News
7.10 CSL
  7.10.1 CSL Corporate Summary
  7.10.2 CSL Business Overview
  7.10.3 CSL Neuromyelitis Optica Drug Major Product Offerings
  7.10.4 CSL Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.10.5 CSL Key News
7.11 Grifols
  7.11.1 Grifols Corporate Summary
  7.11.2 Grifols Business Overview
  7.11.3 Grifols Neuromyelitis Optica Drug Major Product Offerings
  7.11.4 Grifols Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.11.5 Grifols Key News
7.12 Octapharma
  7.12.1 Octapharma Corporate Summary
  7.12.2 Octapharma Business Overview
  7.12.3 Octapharma Neuromyelitis Optica Drug Major Product Offerings
  7.12.4 Octapharma Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.12.5 Octapharma Key News
7.13 CBOP
  7.13.1 CBOP Corporate Summary
  7.13.2 CBOP Business Overview
  7.13.3 CBOP Neuromyelitis Optica Drug Major Product Offerings
  7.13.4 CBOP Neuromyelitis Optica Drug Revenue in Global (2016-2021)
  7.13.5 CBOP Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neuromyelitis Optica Drug Market Opportunities & Trends in Global Market
Table 2. Neuromyelitis Optica Drug Market Drivers in Global Market
Table 3. Neuromyelitis Optica Drug Market Restraints in Global Market
Table 4. Key Players of Neuromyelitis Optica Drug in Global Market
Table 5. Top Neuromyelitis Optica Drug Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Neuromyelitis Optica Drug Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Neuromyelitis Optica Drug Revenue Share by Companies, 2016-2021
Table 8. Global Companies Neuromyelitis Optica Drug Product Type
Table 9. List of Global Tier 1 Neuromyelitis Optica Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optica Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Neuromyelitis Optica Drug Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Neuromyelitis Optica Drug Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Neuromyelitis Optica Drug Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Neuromyelitis Optica Drug Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Neuromyelitis Optica Drug Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Neuromyelitis Optica Drug Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Neuromyelitis Optica Drug Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Neuromyelitis Optica Drug Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Neuromyelitis Optica Drug Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Neuromyelitis Optica Drug Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Neuromyelitis Optica Drug Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Neuromyelitis Optica Drug Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Neuromyelitis Optica Drug Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Neuromyelitis Optica Drug Revenue, (US$, Mn), 2022-2027
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Neuromyelitis Optica Drug Product Offerings
Table 32. Pfizer Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 33. Fresenius Corporate Summary
Table 34. Fresenius Neuromyelitis Optica Drug Product Offerings
Table 35. Fresenius Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 36. Teva Corporate Summary
Table 37. Teva Neuromyelitis Optica Drug Product Offerings
Table 38. Teva Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 39. Sandoz Corporate Summary
Table 40. Sandoz Neuromyelitis Optica Drug Product Offerings
Table 41. Sandoz Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 42. Intas Corporate Summary
Table 43. Intas Neuromyelitis Optica Drug Product Offerings
Table 44. Intas Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 45. Gyjtrs Corporate Summary
Table 46. Gyjtrs Neuromyelitis Optica Drug Product Offerings
Table 47. Gyjtrs Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 48. NANG KUANG Corporate Summary
Table 49. NANG KUANG Neuromyelitis Optica Drug Product Offerings
Table 50. NANG KUANG Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 51. Tianjin Kingyork Corporate Summary
Table 52. Tianjin Kingyork Neuromyelitis Optica Drug Product Offerings
Table 53. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 54. Baxter Corporate Summary
Table 55. Baxter Neuromyelitis Optica Drug Product Offerings
Table 56. Baxter Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 57. CSL Corporate Summary
Table 58. CSL Neuromyelitis Optica Drug Product Offerings
Table 59. CSL Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 60. Grifols Corporate Summary
Table 61. Grifols Neuromyelitis Optica Drug Product Offerings
Table 62. Grifols Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 63. Octapharma Corporate Summary
Table 64. Octapharma Neuromyelitis Optica Drug Product Offerings
Table 65. Octapharma Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)
Table 66. CBOP Corporate Summary
Table 67. CBOP Neuromyelitis Optica Drug Product Offerings
Table 68. CBOP Neuromyelitis Optica Drug Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Neuromyelitis Optica Drug Segment by Type
Figure 2. Neuromyelitis Optica Drug Segment by Application
Figure 3. Global Neuromyelitis Optica Drug Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Neuromyelitis Optica Drug Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Neuromyelitis Optica Drug Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2020
Figure 8. By Type - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 9. By Application - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 10. By Region - Global Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 11. By Country - North America Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 12. US Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 16. Germany Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 17. France Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 24. China Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 28. India Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 30. Brazil Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Neuromyelitis Optica Drug Revenue Market Share, 2016-2027
Figure 33. Turkey Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Neuromyelitis Optica Drug Revenue, (US$, Mn), 2016-2027
Figure 37. Pfizer Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Fresenius Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Teva Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Sandoz Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Intas Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Gyjtrs Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. NANG KUANG Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Tianjin Kingyork Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Baxter Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. CSL Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Grifols Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Octapharma Neuromyelitis Optica Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)